Aviragen Therapeutics and Georgia State University Research Foundation Enter Exclusive License and Sponsored Research Agreeme...
July 05 2016 - 7:00AM
Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota
Pharmaceuticals, Inc.), a pharmaceutical company that is developing
the next generation of antivirals, today announced that it has
entered into an exclusive, worldwide license and sponsored research
agreement with Georgia State University Research Foundation (GSURF)
to jointly develop and commercialize respiratory syncytial virus
(RSV) replication inhibitors discovered by Professor Richard
Plemper and his team in the Institute for Biomedical Sciences
(IBMS) at Georgia State University.
“We are thrilled to begin this collaboration with Dr. Plemper as
we broaden our internal efforts to develop RSV non-fusion inhibitor
compounds to complement BTA585, our fusion inhibitor currently in a
Phase 2a clinical trial,” said Joseph M. Patti, Ph.D., President
and Chief Executive Officer of Aviragen Therapeutics. “This
collaboration with the outstanding team at GSURF will add to
Aviragen’s growing portfolio of novel antivirals, focused on
addressing respiratory infections with significant unmet clinical
needs.”
“My group has generated a portfolio of next generation RSV drug
candidates. We are excited to partner with Aviragen to jointly
develop the full clinical potential of these inhibitors,” said
Richard Plemper, Ph.D., Principal Investigator and head of a drug
discovery laboratory at the IBMS. “RSV infection can be
particularly devastating to infants and the elderly. By joining
forces with Aviragen, we will apply our highly complementary sets
of expertise in an effort to address the problem.”
Dr. Plemper’s research focuses on clinically significant members
of the myxovirus families such as influenza virus and RSV. Studying
the molecular replication mechanism of these pathogens, his
laboratory has developed innovative drug screening technologies for
the identification and characterization of much-needed novel
therapeutics.
About Aviragen Therapeutics, Inc.Aviragen
Therapeutics is focused on the discovery and development of the
next generation of direct-acting antivirals to treat infections
that have limited therapeutic options and affect a significant
number of patients globally. The Company has three product
candidates in active clinical development: vapendavir, an oral
treatment for human rhinovirus upper (HRV) respiratory infections
in moderate-to-severe asthmatics currently being evaluated in the
Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor
that has received Fast Track designation by the U.S. FDA, in Phase
2 development for the treatment and prevention of respiratory
syncytial virus (RSV) infections; and BTA074, a topical antiviral
treatment in Phase 2 development for condyloma caused by human
papillomavirus types 6 & 11. For additional information about
the Company, please visit
www.aviragentherapeutics.com.
Forward Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 that involve known
and unknown risks and uncertainties concerning Aviragen
Therapeutics' business, operations and financial performance. Any
statements that are not of historical facts may be deemed to be
forward-looking statements. Various important factors could cause
actual results, performance, events or achievements to materially
differ from those expressed or implied by forward-looking
statements, including: the Company, the FDA or a similar
regulatory body in another country, a data safety monitoring board,
or an institutional review board delaying, limiting, suspending or
terminating the clinical development of any of the Company's
product candidates at any time for a lack of safety, tolerability,
regulatory or manufacturing issues, or any other reason whatsoever;
the Company's ability to secure, manage and retain qualified
third-party clinical research data management and contract
manufacturing organizations upon which it relies to assist in the
design, development, implementation and execution of the clinical
development of all its product candidates and those organizations'
ability to successfully execute their contracted responsibilities;
the Company's ability to comply with applicable government
regulations in various countries and regions in which we are
conducting, or expect to conduct, clinical trials; and other
cautionary statements contained elsewhere in this press release and
in our Annual Report on Form 10-K, Quarterly Report on Form 10-Q
and our other reports filed with the Securities and Exchange
Commission. There may be events in the future that the Company is
unable to predict, or over which it has no control, and the
Company's business, financial condition, results of operations and
prospects may change in the future. The Company may not update
these forward-looking statements more frequently than quarterly
unless it has an obligation under U.S. Federal securities
laws to do so.
Contacts:
Mark Colonnese
Executive Vice President and Chief Financial Officer
Aviragen Therapeutics, Inc.
(678) 221-3381
mcolonnese@aviragentherapeutics.com
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024